166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo

• Gabriel Helmlinger,
• Rachel Burga,
• Stanley Tam,
• Mithun Khattar,
• Scott Lajoie,
• Kyle Pedro,
• Colleen Foley,
• Alonso Villasmil Ocando,
• Jack Tremblay,
• Benjamin Primack,
• Meghan Langley,
• Dan Thornton,
• Emily Brideau,
• Theresa Ross,
• Gwen Wilmes,
• Sunandan Saha,
• Jeremy Tchaicha,
• Dhruv Sethi,
• Michelle Ols,
• Gary Vanasse,
• Shyam Subramanian,
• Jan ter Meulen

Affiliations

Gabriel Helmlinger

Aff3 grid.418152.bEarly Clinical Development, IMED Biotech Unit, AstraZeneca 35 Gatehouse Drive 02451 Waltham MA USA

Rachel Burga

Northwestern University, Chicago, USA

Stanley Tam

4Department of Anesthesia, Scarborough General Hospital, Ontario, Canada

Mithun Khattar

Obsidian Therapeutics, Cambridge, MA, USA

Scott Lajoie

Obsidian Therapeutics, Cambridge, MA, USA

Kyle Pedro

Obsidian Therapeutics, Cambridge, MA, USA

Colleen Foley

Obsidian Therapeutics, Cambridge, MA, USA

Alonso Villasmil Ocando

Obsidian Therapeutics, Cambridge, MA, USA

Jack Tremblay

Obsidian Therapeutics, Cambridge, MA, USA

Benjamin Primack

Obsidian Therapeutics, Cambridge, MA, USA

Meghan Langley

Obsidian Therapeutics, Cambridge, MA, USA

Dan Thornton

Obsidian Therapeutics, Cambridge, MA, USA

Emily Brideau

Obsidian Therapeutics, Cambridge, MA, USA

Theresa Ross

Obsidian Therapeutics, Cambridge, MA, USA

Gwen Wilmes

Obsidian Therapeutics, Cambridge, MA, USA

Sunandan Saha

Obsidian Therapeutics, Cambridge, MA, USA

Jeremy Tchaicha

Obsidian Therapeutics, Cambridge, MA, USA

Dhruv Sethi

Obsidian Therapeutics, Cambridge, MA, USA

Michelle Ols

Obsidian Therapeutics, Cambridge, MA, USA

Gary Vanasse

Obsidian Therapeutics, Cambridge, MA, USA

Shyam Subramanian

Obsidian Therapeutics, Cambridge, MA, USA

Jan ter Meulen

Obsidian Therapeutics, Cambridge, MA, USA